Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | AKT2 | P31751 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21263297 | 0.79 | ADORA1 (0.61) | SMN1; SMN2ADORA1ADORA3ADORA2ACSNK2A1 | |
| SCHEMBL3210466 | 0.78 | ADORA1 (0.70) | SMN1; SMN2ADORA1ADORA3ADORA2A | |
| SCHEMBL5421997 | 0.76 | ADORA1 (0.41) | SMN1; SMN2ADORA1ADORA3ADORA2ACSNK2A1 | |
| SCHEMBL7386115 | 0.75 | ADORA1 (0.53) | ADORA1ADORA3ADORA2A | |
| SCHEMBL16801763 | 0.68 | NQO2 (0.42) | SMN1; SMN2ADORA1ADORA3ADORA2ACSNK2A1 | |
| SCHEMBL6300995 | 0.67 | KDM4E (0.44) | ADORA1ADORA3ADORA2AMAPT | |
| SCHEMBL6305824 | 0.67 | AURKA (0.58) | SMN1; SMN2ADORA1ADORA3ADORA2ACSNK2A1 | |
| SCHEMBL30490138 | 0.65 | SMN1; SMN2 (0.47) | SMN1; SMN2ADORA1ADORA3ADORA2ACSNK2A1 | |
| SCHEMBL6300137 | 0.65 | SMN1; SMN2 (0.47) | SMN1; SMN2ADORA1ADORA3ADORA2ACSNK2A1 | |
| SCHEMBL2632907 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911469-B2 | Sulfonamide compounds and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-07-25 | — | — | US | disclosed |
| US-6348474-B1 | COMPOUNDS AS ANTIDIABETIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-0995742-A1 | SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | PDE2A, PDE3A, PDE12 | SMN1; SMN2 186/4885ADORA1 307/4885ADORA3 582/4885 |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | PDE2A, PDE3A, PYGM | SMN1; SMN2 1017/4885ADORA1 456/4885ADORA3 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.